Association of ITPA 94C>A genetic polymorphisms with azathioprine induced adverse effects in the South Indian population.

Q2 Pharmacology, Toxicology and Pharmaceutics Drug metabolism and personalized therapy Pub Date : 2023-12-15 eCollection Date: 2024-03-01 DOI:10.1515/dmpt-2023-0061

Reka Deva, Priyadharsini Rajendran, Sivaranjini Ramasamy, Senthamizh Selvan, Kesavan Ramasamy

{"title":"Association of ITPA 94C>A genetic polymorphisms with azathioprine induced adverse effects in the South Indian population.","authors":"Reka Deva, Priyadharsini Rajendran, Sivaranjini Ramasamy, Senthamizh Selvan, Kesavan Ramasamy","doi":"10.1515/dmpt-2023-0061","DOIUrl":null,"url":null,"abstract":"Objectives: Azathioprine (AZA) is an effective immunosuppressant commonly used for malignancy and immune-mediated disorders. The association between genetic polymorphisms and AZA-induced adverse effects has not been elucidated. Hence this study aimed to evaluate the relationship between single nucleotide polymorphisms of ITPA (C94A) with azathioprine-induced adverse effects.Methods: A cross-sectional study was performed on 120 patients who were on AZA therapy for immunobullous disorders and inflammatory bowel disease (IBD). Eligible patients were enrolled from outpatient Departments of dermatology and medical gastroenterology and five mL of blood was collected after obtaining written informed consent. DNA extraction and genotyping were done by phenol-chloroform method and real-time polymerase chain reaction (RT-PCR), respectively.Results: The minor allele frequency of ITPA (A allele) was 30.8 %. The mutant genotypes of ITPA (C94A) were found to have no significant association with overall adverse effects in the South Indian patients on AZA therapy.Conclusions: We report no significant association between ITPA rs1127354 genetic polymorphism and adverse effects in the South Indian patients on AZA therapy.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug metabolism and personalized therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/dmpt-2023-0061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Azathioprine (AZA) is an effective immunosuppressant commonly used for malignancy and immune-mediated disorders. The association between genetic polymorphisms and AZA-induced adverse effects has not been elucidated. Hence this study aimed to evaluate the relationship between single nucleotide polymorphisms of ITPA (C94A) with azathioprine-induced adverse effects.

Methods: A cross-sectional study was performed on 120 patients who were on AZA therapy for immunobullous disorders and inflammatory bowel disease (IBD). Eligible patients were enrolled from outpatient Departments of dermatology and medical gastroenterology and five mL of blood was collected after obtaining written informed consent. DNA extraction and genotyping were done by phenol-chloroform method and real-time polymerase chain reaction (RT-PCR), respectively.

Results: The minor allele frequency of ITPA (A allele) was 30.8 %. The mutant genotypes of ITPA (C94A) were found to have no significant association with overall adverse effects in the South Indian patients on AZA therapy.

Conclusions: We report no significant association between ITPA rs1127354 genetic polymorphism and adverse effects in the South Indian patients on AZA therapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

南印度人群中 ITPA 94C>A 基因多态性与硫唑嘌呤诱导的不良反应的关系。

目的：硫唑嘌呤（AZA）是一种有效的免疫抑制剂，常用于治疗恶性肿瘤和免疫介导的疾病。遗传多态性与 AZA 引起的不良反应之间的关系尚未阐明。因此，本研究旨在评估 ITPA（C94A）的单核苷酸多态性与硫唑嘌呤诱导的不良反应之间的关系：这项横断面研究的对象是120名因免疫球蛋白紊乱和炎症性肠病（IBD）而接受AZA治疗的患者。符合条件的患者在皮肤科和消化内科门诊部登记，在获得书面知情同意后采集 5 mL 血液。DNA提取和基因分型分别采用苯酚-氯仿法和实时聚合酶链反应（RT-PCR）法进行：ITPA的小等位基因（A等位基因）频率为30.8%。在接受 AZA 治疗的南印度患者中，发现 ITPA 的突变基因型（C94A）与总体不良反应无明显关联：我们报告称，在接受 AZA 治疗的南印度患者中，ITPA rs1127354 基因多态性与不良反应之间没有明显关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Drug metabolism and personalized therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

2.30

自引率

0.00%

发文量

期刊介绍： Drug Metabolism and Personalized Therapy (DMPT) is a peer-reviewed journal, and is abstracted/indexed in relevant major Abstracting Services. It provides up-to-date research articles, reviews and opinion papers in the wide field of drug metabolism research, covering established, new and potential drugs, environmentally toxic chemicals, the mechanisms by which drugs may interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions and drug metabolism and excretion. Topics: drug metabolizing enzymes, pharmacogenetics and pharmacogenomics, biochemical pharmacology, molecular pathology, clinical pharmacology, pharmacokinetics and drug-drug interactions, immunopharmacology, neuropsychopharmacology.